Dermata Therapeutics

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell DRMA and other ETFs, options, and stocks.

About DRMA

Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. Its product pipeline includes DMT310, DMT400, and DMT410.

CEO

Gerald T. Proehl

CEOGerald T. Proehl

Employees

Employees8

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

2014

Founded2014

Employees

Employees8

DRMA Key Statistics

Market cap

5.25M

Market cap5.25M

Price-Earnings ratio

—

Price-Earnings ratio—

Dividend yield

—

Dividend yield—

Average volume

176.03K

Average volume176.03K

High today

$0.55

High today$0.55

Low today

$0.5201

Low today$0.5201

Open price

$0.5201

Open price$0.5201

Volume

46.77K

Volume46.77K

52 Week high

$6.95

52 Week high$6.95

52 Week low

$0.435

52 Week low$0.435

DRMA Earnings

-$0.86

-$0.57

-$0.29

$0.00

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Q3 FY22

Estimated

— per share

Estimated— per share

Actual

Expected Nov 14

ActualExpected Nov 14

Dermata Therapeutics

Why Robinhood?

Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. Its product pipeline includes DMT310, DMT400, and DMT410. Show more

DRMA Key Statistics

Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. Its product pipeline includes DMT310, DMT400, and DMT410.